Multiaxis thrust vectoring using axisymmetric nozzles and postexit vanes on an F/A-18 configuration vehicle

A ground-based investigation was conducted on an operational system of multiaxis thrust vectoring using postexit vanes around an axisymmetric nozzle. This thrust vectoring system will be tested on the NASA F/A-18 High Alpha Research Vehicle (HARV) aircraft. The system provides thrust vectoring capability in both pitch and yaw. Ground based data were gathered from two separate tests at NASA Langley Research Center. The first was a static test in the 16-foot Transonic Tunnel Cold-Jet Facility with a 14.25 percent scale model of the axisymmetric nozzle and the postexit vanes. The second test was conducted in the 30 by 60 foot wind tunnel with a 16 percent F/A-18 complete configuration model. Data from the two sets are being used to develop models of jet plume deflection and thrust loss as a function of vane deflection. In addition, an aerodynamic interaction model based on plume deflection angles will be developed. Results from the scale model nozzle test showed that increased vane deflection caused exhaust plume turning. Aerodynamic interaction effects consisted primarily of favorable interaction of moments and unfavorable interaction of forces caused by the vectored jet plume

Epithelial cell–derived secreted and transmembrane 1a signals to activated neutrophils during pneumococcal pneumonia

Airway epithelial cell responses are critical to the outcome of lung infection. In this study, we aimed to identify unique contributions of epithelial cells during lung infection. To differentiate genes induced selectively in epithelial cells during pneumonia, we compared genome-wide expression profiles from three sorted cell populations: epithelial cells from uninfected mouse lungs, epithelial cells from mouse lungs with pneumococcal pneumonia, and nonepithelial cells from those same infected lungs. Of 1,166 transcripts that were more abundant in epithelial cells from infected lungs compared with nonepithelial cells from the same lungs or from epithelial cells of uninfected lungs, 32 genes were identified as highly expressed secreted products. Especially strong signals included two related secreted and transmembrane (Sectm) 1 genes, Sectm1a and Sectm1b. Refinement of sorting strategies suggested that both Sectm1 products were induced predominantly in conducting airway epithelial cells. Sectm1 was induced during the early stages of pneumococcal pneumonia, and mutation of NF-kB RelA in epithelial cells did not diminish its expression. Instead, type I IFN signaling was necessary and sufficient for Sectm1 induction in lung epithelial cells, mediated by signal transducer and activator of transcription 1. For target cells, Sectm1a bound to myeloid cells preferentially, in particular Ly6GbrightCD11bbright neutrophils in the infected lung. In contrast, Sectm1a did not bind to neutrophils from uninfected lungs. Sectm1a increased expression of the neutrophil-attracting chemokine CXCL2 by neutrophils from the infected lung. We propose that Sectm1a is an epithelial product that sustains a positive feedback loop amplifying neutrophilic inflammation during pneumococcal pneumonia

Systemic Inflammation Impairs Attention and Cognitive Flexibility but Not Associative Learning in Aged Rats: Possible Implications for Delirium

Delirium is a common and morbid condition in elderly hospitalized patients. Its pathophysiology is poorly understood but inflammation has been implicated based on a clinical association with systemic infection and surgery and preclinical data showing that systemic inflammation adversely affects hippocampus-dependent memory. However, clinical manifestations and imaging studies point to abnormalities not in the hippocampus but in cortical circuits. We therefore tested the hypothesis that systemic inflammation impairs prefrontal cortex function by assessing attention and executive function in aged animals. Aged (24-month-old) Fischer-344 rats received a single intraperitoneal injection of lipopolysaccharide (LPS; 50 μg/kg) or saline and were tested on the attentional set-shifting task (AST), an index of integrity of the prefrontal cortex, on days 1–3 post-injection. Plasma and frontal cortex concentrations of the cytokine TNFα and the chemokine CCL2 were measured by ELISA in separate groups of identically treated, age-matched rats. LPS selectively impaired reversal learning and attentional shifts without affecting discrimination learning in the AST, indicating a deficit in attention and cognitive flexibility but not learning globally. LPS increased plasma TNFα and CCL2 acutely but this resolved within 24–48 h. TNFα in the frontal cortex did not change whereas CCL2 increased nearly threefold 2 h after LPS but normalized by the time behavioral testing started 24 h later. Together, our data indicate that systemic inflammation selectively impairs attention and executive function in aged rodents and that the cognitive deficit is independent of concurrent changes in frontal cortical TNFα and CCL2. Because inattention is a prominent feature of clinical delirium, our data support a role for inflammation in the pathogenesis of this clinical syndrome and suggest this animal model could be useful for studying that relationship further

Campus Vol VIII N 2

Shaw, Ted. Cover. Picture. 0. Mckenny, Sam. Fiction and Fact From Sports Almanac . Prose. 2. LeFever, Joe. The Fourth Ring . Prose. 3. Lugar, Dick. The Meaning of Campus Government . Prose. 4. Huntington, Ann. Campus Calender Girls: January . Picture. 6. Lashar, Sally. Campus Calender Girls: Febuary . Picture. 6. Omundson, Marilyn. Campus Calender Girls: March . Picture. 6. Nuzum, Gret. Campus Calender Girls: April . Picture. 7. Nussbaum, Nancy. Campus Calender Girls: May . Picture. 7. Morrow, Bobbie. Campus Calender Girls: June . Picture. 7. Walker, Nancy. Campus Calender Girls: July . Picture. 8. Gregory, Mary Lou. Campus Calender Girls: August . Picture. 8. Dutro, Jacquie. Campus Calender Girls: September . Picture. 8. Woodward, Lee. Campus Calender Girls: October . Picture. 9. Thuma, Jane. Campus Calender Girls: November . Picture. 9. Drake, Mary. Campus Calender Girls: December . Picture. 9. Aabye, Nancy. The Dividing Line . Prose. 10. Anonymous. Untitled. Prose. 11. Miller, Bud. Denison\u27s Two new Varsity Sports---Lacrosse and Soccer . Prose. 12. Anonymous. Untitled. Prose. 13. H and S. From Here to Bexley . Prose. 14. Shaw, Ted. Vote Here . Cartoon. 15. Mackimm, Brad. Untitled. Cartoon. 16. Howard Studio. Ricky Helmerichs, Sophomore . Picture. 17

The Vehicle, Fall 1978

Vol. 2, No. 1 Table of Contents FarewellGregory Manifoldpage 4 Visiting HoursCindy Grocepage 5 The Deer KillerG.L. Bullardpage 6 Identity CrisisCindy Grocepage 9 I ScreamDale Stroheckerpage 11 John RobertLee Martinpage 12 Smiling in WinterNancy Cunninghampage 20 Walt Disney Told Us LiesThomas C. Howellpage 20 LakesideMary McDanielpage 21 Heavy LiteratureTerry Kroenungpage 22 Old FriendsMary McDanielpage 27 A Sunny AfternoonJoan O\u27Connorpage 28 Always TomorrowMary McDanielpage 29 Four SunsetsGregory Manifoldpage 30 Come FreeBob Welshpage 32 Faded PinstripesLee Martinpage 33 WindsongCarolyn Perrypage 38 SilenceSylvia Aldertonpage 39 One More TimeCheri Clousepage 40 Grandfather Was IlliterateCindy Grocepage 41 StonehengeGregory Manifoldpage 43 GabsCheri Clousepage 44 Spindley Bare BranchesJeanne Hansenpage 48 Art CoverLafayette Wilson PhotographBill Cochranpage 3 DrawingLafayette Wilsonpage 10 DrawingLafayette Wilsonpage 19 PhotographBill Cochranpage 21 PhotographBarbara Colemanpage 28 DrawingJoyce Bonwellpage 31 PhotographKathy Sanderspage 39 DrawingKathy Sanderspage 42https://thekeep.eiu.edu/vehicle/1035/thumbnail.jp

Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

BACKGROUND: Anti-programmed cell death ligand 1 (PD-L1)/programmed cell death 1 antibodies have shown clinical activity in platinum-treated metastatic urothelial carcinoma, resulting in regulatory approval of several agents, including avelumab (anti-PD-L1). We report ≥2-year follow-up data for avelumab treatment and exploratory subgroup analyses in patients with urothelial carcinoma. METHODS: Patients with previously treated advanced/metastatic urothelial carcinoma, pooled from two cohorts of the phase Ib JAVELIN Solid Tumor trial, received avelumab 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity or withdrawal. End points included best overall response and progression-free survival (PFS) per RECIST V.1.1, overall survival (OS) and safety. Post hoc analyses included objective response rates (ORRs) in subgroups defined by established high-risk/poor-prognosis characteristics and association between time to response and outcome. RESULTS: 249 patients received avelumab; efficacy was assessed in 242 postplatinum patients. Median follow-up was 31.9 months (range 24-43), and median treatment duration was 2.8 months (range 0.5-42.8). The confirmed ORR was 16.5% (95% CI 12.1% to 21.8%; complete response in 4.1% and partial response in 12.4%). Median duration of response was 20.5 months (95% CI 9.7 months to not estimable). Median PFS was 1.6 months (95% CI 1.4 to 2.7 months) and the 12-month PFS rate was 16.8% (95% CI 11.9% to 22.4%). Median OS was 7.0 months (95% CI 5.9 to 8.5 months) and the 24-month OS rate was 20.1% (95% CI 15.2% to 25.4%). In post hoc exploratory analyses, avelumab showed antitumor activity in high-risk subgroups, including elderly patients and those with renal insufficiency or upper tract disease; ORRs were numerically lower in patients with liver metastases or low albumin levels. Objective response achieved by 3 months versus later was associated with longer OS (median not reached (95% CI 18.9 months to not estimable) vs 7.1 months (95% CI 5.2 to 9.0 months)). Safety findings were consistent with previously reported 6-month analyses. CONCLUSIONS: After ≥2 years of follow-up, avelumab showed prolonged efficacy and acceptable safety in patients with platinum-treated advanced/metastatic urothelial carcinoma, including high-risk subgroups. Survival appeared longer in patients who responded within 3 months. Long-term safety findings were consistent with earlier reports with avelumab treatment in this patient population